Inovio Pharma (INO) Misses Q2 EPS by 14c
Tweet
Share
E-mailGet Alerts INO Hot Sheet
Price: $1.15 +5.50%
Financial Fact:
Total operating expenses: 32.74M
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Total operating expenses: 32.74M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Inovio Pharma (NASDAQ: INO) reported Q2 EPS of ($0.39), $0.14 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $273 thousand versus the consensus estimate of $1.21 million.
For earnings history and earnings-related data on Inovio Pharma (INO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla to launch Cybercab in Austin this month - report
- Barclays Upgrades Schott Pharma AG (1SXP:GR) to Overweight
- RBC Capital Downgrades Hermes International (RMS:FP) (HESAY) to Sector Perform
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
